Based on the information available, there is no specific data indicating the exact frequency of gastrointestinal (GI) problems experienced by patients while taking darolutamide. Darolutamide is a second-generation androgen receptor inhibitor (ARI) used for treating non-metastatic castration-resistant prostate cancer [1].

Adverse events (AEs) associated with darolutamide were evaluated in the ARAMIS trial, a randomized, double-blind, placebo-controlled, multicenter phase 3 study [2]. The study reported that the most common AEs (≥10%) in the darolutamide group were fatigue, pain in extremity, and rash [2].

Regarding GI-specific AEs, the ARAMIS trial reported that diarrhea occurred in 15.9% of patients in the darolutamide group and 14.2% in the placebo group [2]. Nausea was reported in 12.2% of patients in the darolutamide group and 10.6% in the placebo group [2]. These GI AEs were not listed among the most common adverse reactions leading to discontinuation of darolutamide [2].

In summary, while there is no specific data on the frequency of GI problems experienced by patients while taking darolutamide, diarrhea and nausea were reported at a slightly higher rate in patients receiving darolutamide compared to placebo [2].

Sources:
[1] DrugPatentWatch.com. Darolutamide. <https://www.drugpatentwatch.com/drugs/darolutamide>.
[2] Fizazi, Karim et al. "N Engl J Med. 2019 Mar 7;380(10):934-944. doi: 10.1056/NEJMoa1817345."